Leírás: All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
Subjects must be able to understand and communicate psoriasis and constipation the investigator and comply with the requirements psoriasis and constipation the study and must give written, signed and dated informed consent before any study related activity is performed.
Subjects must be at least 18 years of age at time of enrollment 3. Patients with chronic moderate to severe plaque type psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light PUVA 4.
Subjects must have a score in the numerical rating scale NRS, see Patients with previous treatment with Apremilast 2. Patients incapable of giving full informed consent.
Patients enrolled in other clinical trials 3. Allergies against Apremilast or any of the inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide red, iron oxide yellow 20 and 30 mg only and iron oxide black 30 mg only psoriasis and constipation.
Rifampicin, Phenobarbital, Carbamazepine, Phenytoin, enzalutamid, mitotan or St John's Wort as concomitant medication 5.
Patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption 6. Allergy to local anaesthetic or latex 7.
Patients with known disposition for excessive keloid formation or wound healing disorders Patients with other forms than chronic plaque type psoriasis especially drug-induced psoriasis Patients who cannot tolerate the complete dose used in this study due to medical conditions e. Patients with depressive symptom in PHQ-D in visit 1 Concomitant medication that can cause psychiatric symptoms Psychiatric disorders Nem:.